SAXAGLIPTIN HYDROCHLORIDE 5mg. IP + METFORMIN 500mg. IP

An antidiabetic medicine is used in the treatment of type 2 diabetes in adult patients. A well-tolerated drug that produces sustained glycemic control for up to 76 weeks, with greater improvements in glycemic parameters compared with either drug alone. (A Pfützner, 2011) Improves glycemic control in patients with type 2 diabetes mellitus inadequately controlled by metformin alone. (André J Scheen, 2010) Offers a potential advantage in achieving glycemic goals for the majority of patients with type 2 diabetes. (LaSalle, 2010) Demonstrates a better safety profile than acarbose and sulfonylureas. (Peng Men, 2018) An effective treatment in improving pancreatic β-cell function. (Edelman, 2010) Offers remarkable reductions in HbA1c, fasting plasma glucose, and postprandial plasma glucose levels. (Peng Men, 2018) A beneficial option for the treatment of patients with type 2 diabetes. (Dhillon, 2015)